Endonovo Therapeutics Inc

Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million

Endonovo's SofPulse® Secures Taiwan FDA Approval

Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution

Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update

New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.